This study was purposed to comparatively analyse the value of PCR and FCM for dynamic monitoring minimal residual disease (MRD) of acute promyelocytic leukemia. The patients with acute promyelocytic leukemia hospitalized in our hospital from January 2011 to December 2012 were observed and all achieved complete remission after remission induction therapy. Before the chemotherapy, the bone marrow cell morphology examination, polymerase-chain reaction (PCR) and multi-parameter flow cytometry (FCM) were performed for each patient. Then the detection results were statistically analyzed. The 477 specimens were achieved from 159 detections for 48 patients. The results showed that 3 specimens were found to be relapsed by bone marrow cell examination, and other specimens were complete remission;PCR detection confirmed 7 positive, and the FCM confirmed 19 positive. There wasn't significant difference between PCR and FCM by kappa test (P > 0.05). It is concluded that FCM is as sensitive as PCR in evaluating the treatment effect of acute promyelocytic leukemia.
Adolescent ; Adult ; Aged ; Female ; Flow Cytometry ; methods ; Humans ; Leukemia, Promyelocytic, Acute ; therapy ; Male ; Middle Aged ; Neoplasm, Residual ; therapy ; Polymerase Chain Reaction ; methods ; Prospective Studies ; Young Adult

Objective: To investigate the influence of Brucine on cell apoptosis of pancreatic cancer CFPAC-1 cells and the possible mechanism. Methods: Brucine in different concentrations were used to treat CFPAC-1 cells. Cell proliferation was determined by MTT assay and cell apoptosis was determined by flow cytometer assay. Mitochondrial membrane potential was examined by JC-1 staining. The protein expression of Bax and Bcl-2 was measured by Western Blot. Results: The growth inhibition rates of CFPAC-1 cells after being treated with 0 (control group), 0.4 and 0.8 mmol/L Brucine for 24, 48 and 72 h were 0, (30.23±0.55)%, (40.61±0.15)%, (46.98±1.27)% and(50.17±0.75)%, (61.23±0.91)%, (70.32±0.40)%, increasing with a concentration- and time-dependent increase, which was higher than that in control group; and the differences between either two groups at different time points were statistically significant (P<0.05). CFPAC-1 cell apoptosis rate after being treated with 0, 0.4 and 0.8 mmol/L Brucine for 48 h was (2.92±0.46)%, (4.64±1.31)% and (13.09±0.65)%, which increased gradually with the increased drug concentration. The apoptotic rate in 0.8 mmol/L treatment group was obviously higher than that in control group, and the difference was statistically significant (P<0.05). With the increase of the drug concentration, the red fluorescence gradually decreased, and the green fluorescence gradually increased, indicating that the mitochondrial membrane potential was severely damaged and thus decreased. The protein expression of Bcl-2 in CFPAC-1 cells were(0.92±0.12), (0.67±0.14)and(0.35±0.14)mmol/L, and the expression of Bax in CFPAC-1 cells were(0.56±0.12), (0.85±0.10)and(1.15±0.12)mmol/L. With the increase of brucine concentration, the expression of Bcl-2 was significantly reduced while the expression of Bax was significantly increased; and the difference was statistically significant (P<0.05). Conclusions Brucine can effectively induce the apoptosis of human pancreatic cancer CFPAC-1 cells through mitochondrial apoptotic pathway by up-regulating the expression of Bax and down-regulating the expression of Bcl-2.